Michael Gelband’s Cellectar Biosciences CLRB Stock Holding History

Michael Gelband’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-48	Closed	-$17K	–	2178
2021 Q2	$17K	Sell	48 -25	-34%	-$10.8K	﹤0.01%	2256
2021 Q1	$35K	Buy	+73	New	+$43.4K	﹤0.01%	2046

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Michael Gelband's CLRB Position: Q3 2021 in Review

Michael Gelband sold out of Cellectar Biosciences (CLRB) in Q3 2021, closing a stake of 48 shares — an estimated $17K sold.

Michael Gelband first reported a position in CLRB in Q1 2021 and held it in 2 quarters. The position peaked at $35K in Q1 2021. 38 funds tracked by Wall St. Rank hold CLRB as of Q3 2021.

Michael Gelband reported no remaining Cellectar Biosciences position as of Q3 2021 after selling out during the quarter.
Michael Gelband sold 48 Cellectar Biosciences shares in Q3 2021, an estimated $17K.
Michael Gelband first reported a position in Cellectar Biosciences in Q1 2021 and held it in 2 quarters.
Michael Gelband's Cellectar Biosciences position peaked at $35K in Q1 2021.
38 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.